PubMed Biomedical Literature Search

{
  "type": "json",
  "example": {
    "query": "GLP-1 obesity",
    "total": 11811,
    "source": "NCBI PubMed E-utilities",
    "results": [
      {
        "doi": "10.1016/j.medcli.2025.107035",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40466247/",
        "pmid": "40466247",
        "title": "GLP-1-based medications: Mechanisms involved in obesity treatment.",
        "authors": [
          "Salvador J"
        ],
        "journal": "Medicina clinica",
        "pubDate": "2025 Jul",
        "abstract": "Thanks to biochemical engineering, the glucagon-like peptide-1 (GLP-1) molecule has emerged as an essential element in the development of diverse agonists and multiagonists, based in the GLP-1 structure for obesity treatment. These new antiobesity medications can reach up to 24% weight loss, which makes possible an effective management of obesity and its complications. GLP-1 agonists affect divers…"
      },
      {
        "doi": "10.1016/j.molmet.2021.101351",
        "url": "https://pubmed.ncbi.nlm.nih.gov/34626851/",
        "pmid": "34626851",
        "title": "GLP-1 physiology informs the pharmacotherapy of obesity.",
        "authors": [
          "Drucker DJ"
        ],
        "journal": "Molecular metabolism",
        "pubDate": "2022 Mar",
        "abstract": "Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-dependent insulin release and reduce glucagon secretion and gastric emptying, enabling their successful development for the treatment of type 2 diabetes (T2D). These agents also inhibit food intake and reduce body weight, fostering investigation of GLP1RA for the treatment of obesity. Here I discuss the physiology of Glucagon-like …"
      }
    ]
  }
}